Clinical Trials Logo

Advanced Solid Tumors clinical trials

View clinical trials related to Advanced Solid Tumors.

Filter by:

NCT ID: NCT03133247 Completed - Clinical trials for Advanced Solid Tumors

A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients

Start date: June 1, 2017
Phase: Phase 1
Study type: Interventional

In many types of human tumors, PD-L1 is highly expressed. Such high expression has often been associated with poor prognosis in cancer patients. SHR-1316 is a humanized IgG4 monoclonal antibody that binds specifically to human PD-L1.

NCT ID: NCT03117101 Completed - Clinical trials for Advanced Solid Tumors

Study of the AL3810 in the Treatment of Advanced Solid Tumor

Start date: March 2014
Phase: Phase 1
Study type: Interventional

This was a monocentric, open label, non-randomised, non-comparative, dose-finding phase I study

NCT ID: NCT03113188 Completed - Clinical trials for Advanced Solid Tumors

CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

Start date: October 25, 2017
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, phase 1b study of CBP501/cisplatin/nivolumab combination administered once every 21 days to patients with advanced solid tumors.

NCT ID: NCT03089645 Completed - Clinical trials for Advanced Solid Tumors

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

Start date: March 21, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics and Immunogenicity of Medi5083 alone or in combination with Durvalumab,Tremelimumab, and/or Docetaxel in adult subjects with advanced solid tumors.

NCT ID: NCT03082209 Completed - Cancer Clinical Trials

A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies

Start date: March 20, 2017
Phase: Phase 1
Study type: Interventional

This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and pharmacokinetic (PK) profile of ABBV-621 for participants with previously-treated solid tumors or hematologic malignancies. Only chemotherapy combination (ABBV-621 + FOLFIRI) enrolling participants with RAS-mutant CRC who have received one prior line of therapy is open for enrollment.

NCT ID: NCT03077607 Completed - Clinical trials for Advanced Solid Tumors

A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors

Start date: November 7, 2016
Phase: Phase 1
Study type: Interventional

This is a study in patients with advanced solid tumors for the investigation of P-gp inhibition and induction on the PK of talazoparib.

NCT ID: NCT03070548 Completed - Clinical trials for Advanced Solid Tumors

A Study of Talazoparib in Patients With Advanced Solid Tumors

Start date: September 2016
Phase: Phase 1
Study type: Interventional

This study will evaluate the mass balance of talazoparib after a single dose of talazoparib.

NCT ID: NCT03010982 Completed - Clinical trials for Advanced Solid Tumors

Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

Start date: June 20, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, open-label, two-part study designed to characterize the PK of an IV dose of approximately 12 µg tazemetostat that contains approximately 500 nCi of [14C] tazemetostat and the ADME of an oral dose of 800 mg tazemetostat that contains approximately 400 µCi of [14C]-labeled tazemetostat in three subjects with B-cell lymphomas or advanced solid tumors.

NCT ID: NCT03000257 Completed - Clinical trials for Advanced Solid Tumors

A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors

Start date: December 14, 2016
Phase: Phase 1
Study type: Interventional

This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of budigalimab. This study will also evaluate the safety and tolerability of budigalimab in combination with Rovalpituzumab Tesirine and budigalimab in combination with venetoclax. The study will consist of 3 parts: budigalimab monotherapy dose escalation and expansion, budigalimab in combination with Rovalpituzumab Tesirine and budigalimab in combination with venetoclax.

NCT ID: NCT02997176 Completed - Clinical trials for Advanced Solid Tumors

An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)

Start date: September 30, 2016
Phase: Phase 1
Study type: Interventional

This is a trial to investigate the pharmacokinetics (PK) and the safety of talazoparib in patients with advanced solid tumors and impaired hepatic function.